SCHEMBL1375665

SCHEMBL1375665

O=C(C=Cc1ccc(Br)cc1)C=Cc1ccc(Br)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F3 P13726 3/20 0.64
CYP2D6 P10635 3/20 0.64
HSD11B1 P28845 2/20 0.64
CYP2C9 P11712 2/20 0.64
TYR P14679 1/20 0.64
CYP1A2 P05177 5/20 0.61
MAPT P10636 4/20 0.60
LMNA P02545 3/20 0.60
PLIN1 O60240 1/20 0.60
ALDH1A1 P00352 1/20 0.60
RECQL P46063 1/20 0.60
PLIN5 Q00G26 1/20 0.60
SMN1; SMN2 Q16637 1/20 0.60
ABHD5 Q8WTS1 1/20 0.60
HSD17B3 P37058 2/20 0.59
ESR1 P03372 1/20 0.58
ESR2 Q92731 1/20 0.58
JUN P05412 1/20 0.56
NFKB1 P19838 1/20 0.56
CYP1B1 Q16678 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2744670 1.00 F3 (0.64) F3CYP2D6HSD11B1CYP2C9TYR
SCHEMBL12144576 0.92 LMNA (0.76) F3CYP2D6HSD11B1CYP2C9TYR
SCHEMBL28819235 0.92 F3 (0.80) F3CYP2D6HSD11B1CYP2C9TYR
SCHEMBL29428454 0.87 ESR1 (0.51) F3CYP2D6HSD11B1CYP2C9TYR
SCHEMBL11139551 0.85 HSD17B3 (0.83) F3CYP2D6HSD11B1CYP2C9TYR
SCHEMBL11139554 0.85 HSD17B3 (0.83) F3CYP2D6HSD11B1CYP2C9TYR
SCHEMBL4224730 0.84 HCAR2 (0.65) CYP2D6CYP2C9TYRCYP1A2MAPT
SCHEMBL119184 0.84 HCAR2 (0.65) CYP2D6CYP2C9TYRCYP1A2MAPT
SCHEMBL119183 0.84 HCAR2 (0.65) CYP2D6CYP2C9TYRCYP1A2MAPT
SCHEMBL28739863 0.82 NFKB1 (0.71) F3CYP2D6HSD11B1CYP2C9TYR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER SHIBATA, HIROYUKI (JP) 2010-06-17 US claimed
US-9006503-B2 Organic electroluminescence devices containing substituted benzo[C]phenanthrenes MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-8710284-B2 Materials for organic electroluminescent devices containing substituted 10-benzo[c]phenanthrenes MERCK PATENT GMBH (DE) 2014-04-29 US disclosed
US-20140114076-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES MERCK PATENT GMBH (DE) 2014-04-24 US disclosed
US-8178727-B2 Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) 2012-05-15 US disclosed
US-20110288292-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES MERCK PATENT GMBH (DE) 2011-11-24 US disclosed
WO-2010083869-A2 MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES MERCK PATENT GMBH (DE) 2010-07-29 WO disclosed
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER SHIBATA, HIROYUKI (JP) 2010-06-17 US disclosed
US-RE29358-E ANTI-MALARIA AND ANTI-TUBERCULOSIS AGENTS AMERICAN CYANAMID COMPANY (US) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152493-A1 BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER MYC, CCNE2, CCNE1 F3 3373/4885CYP2D6 1871/4885HSD11B1 1678/4885
US-20110288292-A1 MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES DDT, DDC, BMI1 F3 2868/4885CYP2D6 351/4885HSD11B1 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.